Non-Comparative, Two-Cohort, Single Arm, Open-Label, Phase 2 Study of Nivolumab *BMS-936558) in classical Hodgkin Lymphoma (cHL) Subjects after Failure of Autologous Stem Cell Transplant (ASCT)

January 18, 2017